IMA Asks Regulator to Probe Quality of Ranbaxy Medicines
News

IMA Asks Regulator to Probe Quality of Ranbaxy Medicines

Views: 635

Ranbaxy

The Indian Medical Association (IMA), that represents medical practitioners, has asked the Drug Controller General of India (DCGI), to investigate the quality of drugs manufactured and sold by RanbaxyBSE -1.07 % in India.

“We will soon be writing to the DCGI asking them to check and investigate if Ranbaxy drugs are of poor quality,” said Narendra Saini, secretary general, IMA. “However, we will continue to prescribe the drugs to our patients, until the investigation proves that the drugs are of poor quality,” added Saini.

A fortnight ago, Ranbaxy had pleaded guilty to criminal charges for manufacturing and distributing certain adulterated drugs manufactured at its two Indian facilities at Poanta Sahib and Dewas. It also pleaded guilty to charges of consistently falsifying data, including annual reports that were submitted to the US Food and Drug Administration (FDA), which were a violation of good manufacturing practice norms prescribed by the US regulator.

Following these revelations, reports suggested that Mumbai-based Jaslok Hospital had advised its doctors not to prescribe Ranbaxy drugs to its patients, however ET could not independently confirm this as the CEO of the hospital Dr RR Pulgaonkar did not respond to ET’s queries.

However KEM hospital, one of Mumbai’s largest government hospitals, has said that it has not taken any decision regarding Ranbaxy-made drugs. Apollo Hospital, a leading private hospital chain also said there are no plans to withdraw Ranbaxy drugs from the hospital.

“There is no directive or review at Apollo with respect to Ranbaxy,” said a spokesperson from Apollo Hospitals. The IMA says that it is unfair to penalise a company without a thorough investigation, and it hopes that the drug controller will make sure that drug companies will not violate the rule of the Drugs and Cosmetics Act. In the last week, Ranbaxy shares have taken a beating, with its share price surrendering 14% from .`460 from the beginning of this month to .`395.55,

Recommended from all portals

Latest News

To Top